AML BCOP EXAM Questions with Correct Answers| Latest Update Guaranteed Success
AML diagnosis 20% blases
t(8;21), inversion (16), t(16;16), t(15;17)
Favorable cytogenetics t(8;21), inv(16), t(16;16)
intermediate cytogenetics normal, 8+, t(9;11)
Unfavorable cytogenetics Deletion 5 or 7, 11q23, t(;11), inv3, t(3;3), t(6;9), t(9;22), abnl
(17p)
Favorable gene mutations normal, NPM1, CEBPA double mutation
Intermediate gene mutation t(8;21), anything 16 with c-KIT mutation
Unfavorable gene mutation FLT3-ITD
Predictors for outcomes Age, PS, cytogenetics, duration of CR
Criteria for CR ANC > 1, Plt > 100, no transfusions, Blasts < 5, no Auer rods, no
extramedullary disease, karyotype absence NOT required
7+3 regimen Cytarabine 100 mg/m2/day IVI x 7 days
Daunorubicin 90 mg/m2/day or idarubicin 12 mg/m2/day x 3 days
Low intensity regimens Clofarabine 20-30 mg/m2/day x5
AZA
AML diagnosis 20% blases
t(8;21), inversion (16), t(16;16), t(15;17)
Favorable cytogenetics t(8;21), inv(16), t(16;16)
intermediate cytogenetics normal, 8+, t(9;11)
Unfavorable cytogenetics Deletion 5 or 7, 11q23, t(;11), inv3, t(3;3), t(6;9), t(9;22), abnl
(17p)
Favorable gene mutations normal, NPM1, CEBPA double mutation
Intermediate gene mutation t(8;21), anything 16 with c-KIT mutation
Unfavorable gene mutation FLT3-ITD
Predictors for outcomes Age, PS, cytogenetics, duration of CR
Criteria for CR ANC > 1, Plt > 100, no transfusions, Blasts < 5, no Auer rods, no
extramedullary disease, karyotype absence NOT required
7+3 regimen Cytarabine 100 mg/m2/day IVI x 7 days
Daunorubicin 90 mg/m2/day or idarubicin 12 mg/m2/day x 3 days
Low intensity regimens Clofarabine 20-30 mg/m2/day x5
AZA
